Abbott Buys Solvay Pharma Unit But Is It Just A Short-Term Fix?
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott will buy the pharma business of its Belgian-based Tricor/TriLipix partner for $6.6 billion in cash; dependence on Humira, Tricor lingers.